Summary
The Delhi High Court is examining Natco Pharma's petition challenging a breast cancer drug patent held by Novartis and Astex. Natco claims the two companies secured duplicate patents for the Ribociclib molecule, unlawfully extending its protection, with the next hearing scheduled for September 16.